Drugs / dscCfaE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01382095 | Jul 2011 → Aug 2012 | escherichia coli infection | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01922856 | Sep 2013 → Feb 2016 | enteritis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dscCfaE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01922856 ↗ |
| Modality | Protein / enzyme biologic | “The purpose of the study is to determine if immunization with a recombinant E. coli protein, dscCfaE, is safe and immunogenic when administered through the skin using a patch.” NCT01382095 ↗ |